Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Isis Stories

2013-01-29 20:21:26

CARLSBAD, Calif., Jan. 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will conduct a conference call and webcast to provide an update on the U.S. Food and Drug Administration (FDA) approval of the marketing of KYNAMRO(TM) (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH). CONFERENCE CALL At 09:30 a.m. Eastern Time, Wednesday, January 30, 2013, Isis will conduct a live audio webcast and conference call....

2013-01-10 08:28:22

HAVANT, United Kingdom, Jan. 10, 2013 /PRNewswire/ -- Xyratex Ltd (NASDAQ: XRTX), a leading provider of data storage technology, today announced Avid® as a new customer for the Xyratex OneStor® storage solution. Avid combines the OneStor hardware foundation with industry-leading Avid ISIS® software to deliver its high density data storage solution for media enterprises. The ISIS 2000 enables cost effective near line storage for accessing and managing media beyond active...

2013-01-08 20:21:26

WAYNE, Pa., Jan. 8, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/isis) announces that a class action lawsuit has been filed in the United States District Court for United States District Court for the Southern District of California on behalf of all persons or entities that purchased the stock of Isis Pharmaceuticals, Inc. ("Isis Pharmaceuticals" or the "Company") (NASDAQ: ISIS) from March 29, 2012 through October 15, 2012, inclusive (the "Class Period")....

2013-01-02 08:22:52

CARLSBAD, Calif., Jan. 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 31(st) Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 1:30 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the...

2012-12-14 08:24:28

CARLSBAD, Calif., Dec. 14, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will review the CHMP opinion on KYNAMRO(TM) in a conference call and webcast on Friday, December 14, 2012 at 8:30 a.m. Eastern Time. This call will be archived for a limited time on Isis' Web site. CONFERENCE CALL At 8:30 a.m. Eastern Time, Friday, December 14, 2012, Isis will conduct a live webcast and conference call. Interested parties may listen to the call by dialing...

2012-12-13 08:26:37

CARLSBAD, Calif., Dec. 13, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the United States Food and Drug administration has granted ISIS-TTR(Rx) fast track designation for the treatment of familial amyloid polyneuropathy (FAP). ISIS-TTR(Rx )is an antisense drug in development with GlaxoSmithKline (GSK) for the treatment of transthyretin (TTR) amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve...

2012-12-11 08:26:40

CARLSBAD, Calif., Dec. 11, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca announced today a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialise ISIS-STAT3(Rx), a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas. Antisense therapies target the proteins involved in disease processes by...

2012-12-10 08:25:37

WESTON, Mass. and CARLSBAD, Calif., Dec. 10, 2012 /PRNewswire/ -- Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders. Biogen Idec and Isis are also developing antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1 under...

2012-12-07 08:24:23

CARLSBAD, Calif., Dec. 7, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from Phase 1 studies of three drugs, ISIS-PTP1B(Rx), ISIS-GCGR(Rx) and ISIS-GCCR(Rx), in development to treat metabolic disorders, including type 2 diabetes. In all three Phase 1 studies, the drugs were safe and well tolerated with early encouraging data that supports the unique mechanism of each drug. All three drugs are part of Isis' metabolic franchise and are designed...

2012-12-03 08:26:45

CARLSBAD, Calif., Dec. 3, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will highlight three drugs from Isis' metabolic franchise in a conference call and webcast on Friday, December 7, 2012 at 12:00 p.m. Eastern Time. This call will be archived for a limited time on Isis' Web site. In this call, Isis will highlight three drugs, ISIS-PTP1B(Rx), ISIS-GCGR(Rx) and ISIS-GCCR(Rx), from its metabolic franchise, and discuss the potential therapeutic...